A Novel NOD2-associated Mutation and Variant Blau Syndrome: Phenotype and Molecular Analysis

REFERENCES

• Philpott DJ, Sorbara MT, Robertson SJ, et al. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014;14:9–23.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276:4812–4818.
   PubMed Web of Science ®Google Scholar
• Begue B, Dumant C, Bambou JC, et al. Microbial induction of CARD15 expression in intestinal epithelial cells via toll-like receptor 5 triggers an antibacterial response loop. J Cell Physiol. 2006;209:241–252.
   PubMed Web of Science ®Google Scholar
• Lecat A, Piette J, Legrand-Poels S. The protein Nod2: an innate receptor more complex than previously assumed. Biochem Pharmacol. 2010;80:2021–2031.
   PubMed Web of Science ®Google Scholar
• Barnich N, Aguirre JE, Reinecker HC, et al. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition. J Cell Biol. 2005;170:21–26.
   PubMed Web of Science ®Google Scholar
• Tattoli I, Travassos LH, Carneiro LA, et al. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol. 2007;29:289–301.
   PubMed Web of Science ®Google Scholar
• Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol. 2009;4:365–398.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012;12:44–51.
   PubMed Web of Science ®Google Scholar
• Windheim M, Lang C, Peggie M, et al. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J. 2007;404:179–190.
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yin C, Pandey A, et al. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem. 2007;282:36223–36229.
   PubMed Web of Science ®Google Scholar
• Zhao L, Lee JY, Hwang DH. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem Pharmacol. 2008;75:1515–1525.
   PubMed Web of Science ®Google Scholar
• Shen M, Moran R, Tomecki KJ, Yao Q. Granulomatous disease associated with NOD2 sequence variants and familial camptodactyly: An intermediate form of NOD2-associated diseases? Semin Arthritis Rheum. 2015;45:357–360.
   Google Scholar
• Caso F, Galozzi P, Costa L, et al. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn’s disease. RMD Open. 2015;1:e000097.
   PubMed Web of Science ®Google Scholar
• Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr. 1985;107:689–693.
   PubMed Web of Science ®Google Scholar
• Arostegui JI, Arnal C, Merino R, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56:3805–3813.
   PubMed Web of Science ®Google Scholar
• Rose CD, Arostegui JI, Martin TM, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum. 2009;60:1797–1803.
   Google Scholar
• Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014;13:1220–1229.
   PubMed Web of Science ®Google Scholar
• Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr Rheumatol Online J. 2014;12:33.
   PubMed Web of Science ®Google Scholar
• Rose CD, Pans S, Casteels I, et al. Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology (Oxford). 2015;54:1008–1016.
   PubMed Web of Science ®Google Scholar
• Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet. 1996;59:1097–1107.
   PubMed Web of Science ®Google Scholar
• Moreira LO, Zamboni DS. NOD1 and NOD2 Signaling in infection and inflammation. Front Immunol. 2012;3:328.
   PubMed Web of Science ®Google Scholar
• Rose CD, Wouters CH, Meiorin S, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 2006;54:3337–3344.
   PubMed Web of Science ®Google Scholar
• Saini SK, Rose CD. Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheumatol. 1996;23:396–399.
   PubMed Web of Science ®Google Scholar
• Dhondt V, Hofman S, Dahan K, Beele H. Leg ulcers: a new symptom of Blau syndrome? Eur J Dermatol. 2008;18:635–637.
   PubMed Web of Science ®Google Scholar
• Yotsumoto S, Takahashi Y, Takei S, et al. Early onset sarcoidosis masquerading as juvenile rheumatoid arthritis. J Am Acad Dermatol. 2000;43:969–971.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Kawaguchi Y, Shimojo N, et al. A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early-onset sarcoidosis? Mod Rheumatol. 2013;23:837–839.
   PubMed Web of Science ®Google Scholar
• Jakopin Z. Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. J Med Chem. 2014;57:6897–6918.
   PubMed Web of Science ®Google Scholar
• Mohanan V, Grimes CL. The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease. J Biol Chem. 2014;289:18987–18998.
   PubMed Web of Science ®Google Scholar
• Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105:1195–1197.
   PubMed Web of Science ®Google Scholar